Document is current

Article History

Received: 18 November 2024

Accepted: 23 January 2025

First Online: 28 February 2025

Declarations

:

: Karsten Weller reports grants from Novartis and Takeda outside the submitted work and personal fees from CSL Behring, Novartis, Moxie, and Takeda outside the submitted work. Tonya Winders receives funds from unbranded disease awareness and education from Novartis, AstraZeneca, Sanofi-Regeneron, Amgen, Roche, and Genentech outside of the submitted work. At the time of study conduct Tonya was also employed by the Allergy and Asthma Network. Jessica McCarthy is an employee of Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Tara Raftery is an employee of Novartis Ireland Ltd., Dublin, Ireland. Pallavi Saraswat is an employee of Novartis Healthcare Pvt. Ltd, Hyderabad, India. Cristina Constantinescu is an employee of Ipsos SA (Basel, Switzerland), a consulting company paid by Novartis for the design, execution, and analysis of the study, and confirm no conflicts of interest. Maria-Magdalena Balp is an employee of Novartis Pharma AG, Basel, Switzerland. Jonathan A. Bernstein reports grants from Novartis, Astra Zeneca, Sanofi-Regeneron, Amgen, Roche, Allakos, Celldex, CSL Behring, Takeda/Shire, BioCryst, Pharming, Ionis, BioMarin and Genentech outside the submitted work. Personal fees from Novartis, Astra Zeneca, Sanofi-Regeneron, Amgen, Roche, Allakos, Celldex, CSL Behring, Takeda/Shire, BioCryst, Pharming, Ionis, BioMarin and Genentech outside the submitted work.

: This study was conducted in accordance with the ethical principles laid down in the Declaration of Helsinki. IRB / Ethical approval was sought for this study based on the rationale that while the study includes “living people” who will complete the self-administered quantitative internet-based survey, there will be no articles or substances tested; hence Ipsos and the sponsor do not believe that these “living people” would be classified as “human subjects”. An exemption from ongoing oversight was sought after and obtained from an IRB, who reviewed and granted international approval. Informed opt-in consent was sought from respondents before fieldwork. Regardless of the sample origin, all participants electronically confirmed the read receipt of their informed consent forms before proceeding with the survey. Compliance with Novartis and regulatory standards provided assurance that the rights, safety, and well-being of patients participating in non-interventional studies are protected, consistent with the principles that have their origin in the Declaration of Helsinki.